文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

Mavacamten对梗阻性肥厚型心肌病患者心肺运动试验指标的影响:EXPLORER-HCM试验二次分析

Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial.
PubMed 文献 · JAMA Cardiol · 2023-01-01

EXPLORER-HCM试验二次分析纳入251例有症状的梗阻性肥厚型心肌病患者,随机接受mavacamten或安慰剂治疗30周。Mavacamten组在峰值VE/VCO2比值、峰值METs、峰值循环功率、峰值PETCO2及运动时间等多项心肺运动试验指标上较安慰剂组显著改善,提示其可广泛改善最大运动能力及亚极量运动耐受性。

要点

  • Mavacamten改善峰值VE/VCO2比值、峰值METs、峰值循环功率及峰值PETCO2等多项CPET指标。
  • Mavacamten还改善VE/VCO2斜率和通气功率等非峰值运动CPET参数。
  • 上述结果提示mavacamten对梗阻性HCM患者运动生理具有广泛获益。

核心结论

  • Mavacamten改善了峰值氧摄取以外的一系列心肺运动试验参数,表明其对最大运动能力具有一致且广泛的益处,并对亚极量运动耐受性产生有利影响。

研究设计与样本

  • EXPLORER-HCM研究为随机、双盲、安慰剂对照的3期试验,在13个国家68个心血管中心开展,共纳入251例有症状的梗阻性肥厚型心肌病患者,按1:1随机分配至mavacamten或安慰剂组。

主要发现

  • 与安慰剂相比,mavacamten显著改善峰值VE/VCO2比值(最小二乘均值差异-2.2,95%CI -3.05至-1.26,P<.001)、峰值METs(差异0.4,95%CI 0.17-0.60,P<.001)、峰值循环功率(差异372.9 mL/kg/min×mm Hg,95%CI 153.12-592.61,P=.001)和峰值PETCO2(差异2.0 mm Hg,95%CI 1.12-2.79,P<.001)。
  • Mavacamten还改善峰值运动时间(最小二乘均值差异0.7分钟,95%CI 0.13-1.24,P=.02)。
  • 非峰值运动CPET参数方面,VE/VCO2斜率(差异-2.6,95%CI -3.58至-1.52,P<.001)和通气功率(差异0.6 mm Hg,95%CI 0.29-0.90,P<.001)均显著改善,利于mavacamten组。

临床怎么用

  • 对于有症状的梗阻性肥厚型心肌病患者,mavacamten治疗可改善多项心肺运动试验指标,提示其在最大及亚极量运动能力方面的获益,可结合CPET评估治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Mavacamten, a cardiac myosin inhibitor, improved peak oxygen uptake (pVO2) in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in the EXPLORER-HCM study. However, the full extent of mavacamten's effects on exercise performance remains unclear. OBJECTIVE: To investigate the effect of mavacamten on exercise physiology using cardiopulmonary exercise testing (CPET). DESIGN, SETTING, AND PARTICIPANTS: Exploratory analyses of the data from the EXPLORER-HCM study, a randomized, double-blind, placebo-controlled, phase 3 trial that was conducted in 68 cardiovascular centers in 13 countries. In total, 251 patients with symptomatic obstructive HCM were enrolled. INTERVENTIONS: Patients were randomly assigned in a 1:1 ratio to mavacamten or placebo. MAIN OUTCOMES AND MEASURES: The following prespecified exploratory cardiovascular and performance parameters were assessed with a standardized treadmill or bicycle ergometer test protocol at baseline and week 30: carbon dioxide output (VCO2), minute ventilation (VE), peak VE/VCO2 ratio, ventilatory efficiency (VE/VCO2 slope), peak respiratory exchange ratio (RER), peak circulatory power, ventilatory power, ventilatory threshold, peak metabolic equivalents (METs), peak exercise time, partial pressure of end-tidal carbon dioxide (PETCO2), and VO2/workload slope. RESULTS: Two hundred fifty-one patients were enrolled. The mean (SD) age was 58.5 (11.9) years and 59% of patients were male. There were significant improvements with mavacamten vs placebo in the following peak-exercise CPET parameters: peak VE/VCO2 ratio (least squares [LS] mean difference, -2.2; 95% CI, -3.05 to -1.26; P < .001), peak METs (LS mean difference, 0.4; 95% CI, 0.17-0.60; P < .001), peak circulatory power (LS mean difference, 372.9 mL/kg/min × mm Hg; 95% CI, 153.12-592.61; P = .001), and peak PETCO2 (LS mean difference, 2.0 mm Hg; 95% CI, 1.12-2.79; P < .001). Mavacamten also improved peak exercise time compared with placebo (LS mean difference, 0.7 minutes; 95% CI, 0.13-1.24; P = .02). There was a significant improvement in nonpeak-exercise CPET parameters, such as VE/VCO2 slope (LS mean difference, -2.6; 95% CI, -3.58 to -1.52; P < .001) and ventilatory power (LS mean difference, 0.6 mm Hg; 95% CI, 0.29-0.90; P < .001) favoring mavacamten vs placebo. CONCLUSIONS AND RELEVANCE: Mavacamten improved a range of CPET parameters beyond pVO2, indicating consistent and broad benefits on maximal exercise capacity. Although improvements in peak-exercise CPET parameters are clinically meaningful, the favorable effects of mavacamten on submaximal exertional tolerance provide further insights into the beneficial impact of mavacamten in patients with obstructive HCM. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03470545.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Wheeler MT, Olivotto I, Elliott PM, et al. Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial. JAMA Cardiol. 2023. PMID: 36652223. doi:10.1001/jamacardio.2022.5099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。